- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Shield Therapeutics PLC (STXS)
Shield Therapeutics PLC stock price live, this page displays LON STXS stock exchange data. View the STXS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Shield Therapeutics PLC real time stock price chart below.
What Is the Shield Therapeutics PLC Stock Price Today?
The Shield Therapeutics PLC stock price today is 5.43.
What Is the Stock Symbol for Shield Therapeutics PLC?
The stock symbol for Shield Therapeutics PLC is "STXS."
What Stock Exchange Does Shield Therapeutics PLC Trade On?
Shield Therapeutics PLC is listed and trades on the London stock exchange.
Is Shield Therapeutics PLC a Good Stock to Buy?
Determining whether Shield Therapeutics PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the STXS quote. (ISIN: GB00BYV81293)
What Is the Shield Therapeutics PLC Stock Price Today?
The Shield Therapeutics PLC stock price today is 5.43.
What Is the Stock Symbol for Shield Therapeutics PLC?
The stock symbol for Shield Therapeutics PLC is "STXS."
What Stock Exchange Does Shield Therapeutics PLC Trade On?
Shield Therapeutics PLC is listed and trades on the London stock exchange.
Is Shield Therapeutics PLC a Good Stock to Buy?
Determining whether Shield Therapeutics PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the STXS quote. (ISIN: GB00BYV81293)
5.43
-0.07(-1.27%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.43
5.43
52 wk Range
3.70
12.50
STXS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.435.43
52 wk Range
3.7012.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
STXS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
16.67
Upside
+206.94%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock price movements are quite volatile
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 16.67
(+206.94% Upside)
Shield Therapeutics PLC Earnings Call Summary for Q2/2026
- Shield Therapeutics H1 2026 revenue rose 41% YoY to $30.4M; ACCRUFER sales up 5%, but shares plunged 22% to $4.50 amid Medicaid headwinds.
- Company achieved EBIT profitability in H1 2026, reaffirmed full-year profitability target despite New York Medicaid prior authorization policy pressuring pricing.
- Commercial insurance prescriptions jumped 27% in H1 as Shield pivoted away from affected Medicaid segment; net price per script rose to $208 in Q2 from $190.
- Cash reserves declined to $8.3M from $12.4M in Q1; management said no additional capital raise needed and maintains $450M peak revenue target through 2035.
- South Korea launch expected 2027 with $1M+ milestone; China approval also anticipated 2027; new McKesson oncology partnership targets 400+ Texas clinics.
Last Updated: 07/30/2026, 10:16 PM
Read Full TranscriptEarnings
Latest Release
Aug 20, 2026
EPS / Forecast
-- / --
Revenue / Forecast
30.37M / --
Compare STXS to Peers and Sector
Metrics to compare | STXS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSTXSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.7x | 9.6x | −0.4x | |
PEG Ratio | −0.13 | 0.13 | 0.00 | |
Price/Book | −4.7x | 1.7x | 2.6x | |
Price / LTM Sales | 1.4x | 1.5x | 3.0x | |
Upside (Analyst Target) | 172.7% | 31.6% | 47.5% | |
Fair Value Upside | Unlock | 14.1% | 6.7% | Unlock |
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Shield Therapeutics (STXS) Stock Price Today?
The Shield Therapeutics stock price today is 5.43 GBP.
What Stock Exchange Does Shield Therapeutics Trade On?
Shield Therapeutics is listed and trades on the London Stock Exchange.
What Is the Stock Symbol for Shield Therapeutics?
The stock symbol for Shield Therapeutics is "STXS."
What Is the Shield Therapeutics Market Cap?
As of today, Shield Therapeutics market cap is 58.10M GBP.
What Is Shield Therapeutics's Earnings Per Share (TTM)?
The Shield Therapeutics EPS (TTM) is -0.01.
When Is the Next Shield Therapeutics Earnings Date?
Shield Therapeutics will release its next earnings report on Dec 02, 2026.
From a Technical Analysis Perspective, Is STXS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Shield Therapeutics Stock Split?
Shield Therapeutics has split 0 times.
How Many Employees Does Shield Therapeutics Have?
Shield Therapeutics has 61 employees.
What is the current trading status of Shield Therapeutics (STXS)?
As of Sep 07, 2026, Shield Therapeutics (STXS) is trading at a price of 5.43 GBP, with a previous close of 5.50 GBP. The stock has fluctuated within a day range of 5.43 GBP to 5.43 GBP, while its 52-week range spans from 3.70 GBP to 12.50 GBP.
What Is Shield Therapeutics (STXS) Price Target According to Analysts?
The average 12-month price target for Shield Therapeutics is 16.67 GBP, with a high estimate of 23 GBP and a low estimate of 12 GBP. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +206.94% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.